CHMFL-ABL-053

• CAT Number: I006109
• CAS Number: 1808287-83-3
• Molecular Formula: C28H26F3N7O2
• Molecular Weight: 549.56
• Purity: ≥95%
• Synonyms: CHMFL-ABL-053; CHMFL-ABL053; CHMFL-ABL 053.;2‑((3-Amino-4-methylphenyl)amino)‑N‑(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide
• Target: MAPK/ERK Pathway
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4°C for short term ,or -20 °C for long term
• IUPAC Name: 2-(3-amino-4-methylanilino)-4-(methylamino)-N-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]pyrimidine-5-carboxamide
• InChI: InChI=1S/C28H26F3N7O2/c1-15-7-9-19(12-22(15)32)36-27-34-14-21(24(33-3)38-27)26(40)37-23-13-20(10-8-16(23)2)35-25(39)17-5-4-6-18(11-17)28(29,30)31/h4-14H,32H2,1-3H3,(H,35,39)(H,37,40)(H2,33,34,36,38)
• InChIKey: GXMFPDCIAWSZFR-UHFFFAOYSA-N
• SMILES: CC1=C(C=C(C=C1)NC2=NC=C(C(=N2)NC)C(=O)NC3=C(C=CC(=C3)NC(=O)C4=CC(=CC=C4)C(F)(F)F)C)N

CHMFL-ABL-053(CAT: I006109) is a potent and selective allosteric inhibitor of the BCR-ABL1 tyrosine kinase, widely studied for its potential in treating chronic myeloid leukemia (CML) and other BCR-ABL1-driven malignancies. Unlike ATP-competitive inhibitors, CHMFL-ABL-053 binds to the myristoyl pocket of the kinase, disrupting protein conformation and impairing its activity. This unique mechanism of action makes it effective against mutant forms of BCR-ABL1, including those resistant to conventional inhibitors. CHMFL-ABL-053 is a critical tool for investigating resistance mechanisms, exploring BCR-ABL1 biology, and developing advanced therapeutic strategies for hematological cancers.